Skip to content
lifestyle.small-bizsense.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
UroGen Pharma Ltd.
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
March 30, 2026
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
March 30, 2026
UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence
March 13, 2026
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 6, 2026
UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results
March 2, 2026
UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors
March 2, 2026
ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC
February 27, 2026
UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference
February 24, 2026
UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026
February 23, 2026
UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
February 10, 2026
←
Previous Page
1
2